Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Center for Complementary and Alternative Medicine (NCCAM) |
---|---|
Information provided by: | National Center for Complementary and Alternative Medicine (NCCAM) |
ClinicalTrials.gov Identifier: | NCT00010855 |
Analgesics and sedatives administered to control distress from minimally invasive surgical procedures have limited effectiveness and serious side effects. Unabated distress not only interferes with smooth progression of the ongoing procedure, but can elicit adverse responses when patients need additional intervention. The long-term objective of this research is to provide a safe and practical behavioral method for reducing cognitive and physiologic distress associated with invasive procedures. Currently, this method should benefit at least 8 million patients annually in the US.
Extrapolating the risk of intravenous conscious sedation to the number of invasive procedures performed annually, we predict that 47,000 patients will suffer serious cardiorespiratory complications and 2,600 will die. These numbers do not include effects of the psychological damage inflicted by poorly managed procedure-related stress on patients' subsequent health behavior. This application sets out to pursue three aims: 1) Prospectively determine the impact of self-hypnotic relaxation on cognitive and physiologic distress during tumor embolizations; 2) Prospectively determine the impact of self-hypnotic relaxation on distress in the postoperative period; 3) Determine the impact of intraprocedural self-hypnotic relaxation on distress during subsequent tumor embolization. We hypothesize that: 1) Self-hypnotic relaxation decreases cognitive and physiologic distress during tumor embolizations. 2) Self-hypnotic relaxation decreases cognitive and physiologic distress after tumor embolization when post-embolization ischemia is expected to induce painful stimuli and systemic distress. 3) The beneficial effect of self-hypnotic coping skills acquired during an invasive procedure carries over to the next invasive procedure. Upon completion, the efficacy and durability of procedural administration of nonpharmacologic analgesia will be known by a rigorous and practical assessment. The relative performance of self-hypnotic relaxation will be quantified compared to standard care and empathic controls in a well-characterized population of patients within the controlled and monitored environment of a busy interventional radiology practice. Results from this competing renewal will provide the next level of data needed for future study design to determine broad clinical utility in a multicenter randomized controlled trial.
Condition | Intervention | Phase |
---|---|---|
Pain Anxiety |
Behavioral: Self-hypnotic relaxation |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Nonpharmacologic Analgesia for Invasive Procedures |
Ages Eligible for Study: | 18 Years to 90 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |
Beth Israel Deaconess Medical Center | |
Boston, Massachusetts, United States, 02115 |
Principal Investigator: | Elvira V. Lang, MD | Beth Israel Deaconess Medical Center |
Study ID Numbers: | R01 AT000002 |
Study First Received: | February 2, 2001 |
Last Updated: | August 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00010855 History of Changes |
Health Authority: | United States: Federal Government |
hypnosis relaxation invasive medical procedures interventional radiology conscious sedation anesthesia complications |
cost analysis Interventional procedures, complications Angiography Nephrostomy Hepatic chemoembolization Fibroid Embolization |
Myofibroma Hypnotics and Sedatives Central Nervous System Depressants |
Anesthetics Pain Leiomyoma |
Therapeutic Uses Physiological Effects of Drugs Hypnotics and Sedatives |
Central Nervous System Depressants Central Nervous System Agents Pharmacologic Actions |